Chairman, GI Oncology
M.D. Anderson Cancer Center
Heidelberg University, Germany
Director, GI / Liver
Johns Hopkins University
Chief, Medical Oncology
University of California - SF
to Use This Site
Professor Eileen O'Reilly
has recently co-authored
100 Questions and Answers About Pancreatic Cancer
as published by Jones & Bartlett. More information
about this practical book, including the means to buy
it directly from the Publishers web site ($16.95), is
found at the following link:
Would you like to speak
with an experienced counselor about how pancreatic cancer is
affecting your life?
Call 1-800-525-3777 for free counseling
on our Cancer Information and Counseling Line (CICL) from 8:30
to 4:30 (U.S. Mountain Time) Monday thru Friday.
This service is for all
who are affected by pancreatic cancer and is provided in collaboration
with the University of Colorado Cancer Center.
Asked Questions on Pancreatic Cancer
Answers to questions about pancreatic cancer: covers such areas
as definitions, pancreatic cancer stages, symptoms, diagnosis,
prognosis, medical treatment, the Whipple procedure surgery,
support and other related issues
Cancer Clinical Trials Database
The world's largest listing of clinical
trials for pancreatic cancer
Find a clinical trial, review cancer research and emerging cancer
Cancer Medical Literature
Information from medical journals, clinical trials, press releases
and news sources
Orientation: new pancreatic cancer treatment findings
in Pancreatic Cancer
Highlights of recent findings in
pancreatic cancer treatment and research; includes clinical trial
results, research results, treatment results and other matters
of interest in cancer of the pancreas. Sign up for our free monthly Select
Abstracts email newsletter. Click here
to learn more
Tumors - Information
on islet-cell and carcinoid cancers
- Neuroendocrine and Carcinoid Overview
Neuroendocrine Research Results
Carcinoid & Neuroendocrine
Neuroendocrine and Carcinoid
and Carcinoid Links
3 Study for those at High Risk for Pancreatic Cancer
Stand for a Cause
Run with a Passion
Join the Team
The program includes a training
schedule, a coach, entry fees, weekly runs, a racing shirt, prizes,
encouragement and support. For information call Toll Free 1-877-647-0400
or send an email to firstname.lastname@example.org
Please consider running in one of
our 2008 cities
Atlanta Half Marathon
Big Sur Half
Park to Park 10 Miler
Houston Marathon (Half)
US Half Marathon
Also, we will continue:
Dedicate-A-Race (run anywhere)
Virtual Race (you don't have to run)
Stay tuned for updates
and please contact us for more information!
Call Toll Free 1-877-647-0400
or send an email to email@example.com
Read these stories
of long-term pancreatic cancer survivors by clicking here
Corner for Whipple Survivor Research
"Pancreatica.org is a site that MUST be searched by anyone
looking for a comprehensive listing of pancreatic cancer clinical
trials. It is well organized, readable and easy to navigate."
Howard Fuller, Medical
Stanford University Medical Center
Contribute to Pancreatica Now
- Join us in our effort to fight
pancreatic cancer. Your contribution allows Pancreatica.org to
deliver timely, unique and critical information to those in need.
For more information click here.
- Please send
your tax-deductible donations to:
149 Bonifacio Place
In this age of molecular
biology and armed with new understandings about the role that
genes play in pancreatic cancer, familial registries are increasingly
a powerful resource to help gain a better understanding of the
disease - and hence better detection or treatment possibilities.
There are about fifteen cancer
registries worldwide that are specific to cancer of the pancreas
For more information please click here
access to all abstracts back to 2003, please click here
Capecitabine in Combination with
Docetaxel and Mitomycin C in Patients with Pre-Treated Tumours:
Results of an Extended Phase-I Trial.
Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B,
Hochhaus A, Hofheinz RD.
Br J Cancer. 2007 Dec 3;97(11):1475-9; Epub 2007 Nov 13. Medizinische
Fakultät Mannheim der Universität Heidelberg, Germany.
[Link to Abstract]
Long-Term Survival on Capecitabine
in Two Gemcitabine Refractory Pancreatic Cancer Patients. Is
There a Pharmacogenetic Explanation?
Saif MW, Kang SP, Ledbetter
L, Steg A, Diasio R, Johnson M.
JOP. 2007 Nov 9;8(6):799-805. Yale University School of Medicine.
New Haven, Connecticut; University of Alabama at Birmingham,
[Link to Abstract]
Poxvirus-Based Vaccine Therapy for Patients with Advanced
Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham
J, Seo KS, Kim DW, Marshall J.
J Transl Med. 2007 Nov 26;5:60. Division of Surgical Oncology,
Columbia University, New York.
with Gemcitabine and Mitomycin C in Pancreatic Carcinoma: Results
in Locally Recurrent Tumors and Advanced Tumor Stages.
Vogl TJ, Zangos S, Heller
M, Hammerstingl RM, Böcher E, Jacob U, Bauer RW.
Rofo. 2007 Nov;179(11):1181-8. Institut für Diagnostische
und Interventionelle Radiologie, J. W. Goethe-Universität
- To all select
- Select Links sm in Pancreatic Cancer
Genentech now offers its
Single Point of Contact (SPOC) program for aid in any reimbursement
issues related to Tarceva (in use for pancreatic cancer). Please click here
Roche Clinical Trial Protocol Registry. Please click here
The Pancreatic Duct. Please click here
- Recent News Articles
on Pancreatic Cancer
Alliance news summaries click here
Google Newswire click here
continues to support legislative and other effort aimed at increasing
the funding support for pancreatic cancer treatment and research.
- Pancreatic cancer is the most
aggressive of the cancers
- Pancreatic cancer causes more
than 1% of all death in the U.S.
- Pancreatic cancer is the least
funded of the major cancers
Cancer is the second most common
cause of death in the developed world, behind cardiovascular
disease. Pancreatic cancer is the fourth most common cause of
cancer mortality (behind lung cancer, colorectal cancer and breast
250 people in North America and
Europe will die today from pancreatic cancer. (90,000 deaths
The U.S. National Cancer Institute
funds pancreatic cancer research at shockingly low levels (year
2005-07 figures). Pancreatic cancer research receives (per mortality):
of the funding of breast cancer (but causes 82% of the mortality)
17% of the funding of prostate
cancer (but causes more mortality)
41% of the funding of colorectal
cancer (but causes 63% of the mortality)
Supporters of Our Effort Against Pancreatic
Compassionate generosity from the philanthropic and business
Are We Doing?
Please give us feedback